Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens
Crossref DOI link: https://doi.org/10.1007/s40261-017-0526-z
Published Online: 2017-04-06
Published Print: 2017-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Puenpatom, Amy
Hull, Michael
McPheeters, Jeffrey
Schwebke, Kay
Funding for this research was provided by:
Merck
License valid from 2017-04-06